FAQ Library 

FAQ Library  published on March 27, 2015
Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients.
FAQ Library  published on December 20, 2013 in Pharmacologic
Dr. Neil Shah discusses the efficacy and safety considerations of the non-kinase inhibitor omacetaxine.
FAQ Library  published on November 22, 2013 in Pharmacologic
Dr. Neil Shah discusses the efficacy and safety considerations of bosutinib therapy.
FAQ Library  published on November 22, 2013 in Assess & Monitor
Dr. Susan O'Brien discusses the roles of Sokal and Hansford risk calculations in prognosis and treatment.
FAQ Library  published on October 18, 2013 in Pharmacologic
Dr. Neil Shah discusses the efficacy and safety considerations of dasatinib therapy.
FAQ Library  published on October 18, 2013 in Practice
Dr. Jorge Cortes defines chronic-phase CML.
FAQ Library  published on September 20, 2013 in Practice
Dr. Susan O'Brien discusses the recommendations for monitoring a mutation analysis in CML.
FAQ Library  published on September 20, 2013 in Practice
Dr. Jorge Cortes discusses when you should switch to an alternative TKI.
FAQ Library  published on August 23, 2013 in Pharmacologic
Dr. Neil Shah discusses the efficacy and safety considerations of nilotinib therapy.
FAQ Library  published on August 23, 2013 in Practice
Dr. Susan O'Brien discusses the most recent updates to the NCCN Guidelines for CML.
Page 2 of 3
Results 11 - 20 of 23